LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Search

Amgen Inc

Chiusa

SettoreSettore sanitario

356.59 1.23

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

344.71

Massimo

354.3

Metriche Chiave

By Trading Economics

Entrata

486M

1.8B

Vendite

-1.3B

8.6B

P/E

Media del settore

23.989

50.958

EPS

5.15

Rendimento da dividendi

2.86

Margine di Profitto

21.107

Dipendenti

31,500

EBITDA

-1.2B

3.9B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+1.69% upside

Dividendi

By Acuity

Rendimento da dividendi

Media del settore

2.86%

2.41%

Utili prossimi

4 ago 2026

Prossima data del Dividendo

11 set 2026

Prossima data del' Ex Dividendo

21 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2.7B

186B

Apertura precedente

355.36

Chiusura precedente

356.59

Notizie sul Sentiment di mercato

By Acuity

36%

64%

104 / 342 Classifica in Healthcare

Amgen Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 giu 2026, 23:01 UTC

Amgen Inc shares are lower in after-market hours, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

23 giu 2026, 20:06 UTC

Amgen Inc shares are higher since Monday's close, reaching a session high earlier today. No specific company news was identified to explain the movement.

22 giu 2026, 19:33 UTC

Biotechnology stocks support Amgen Inc's upward momentum today, with shares higher since Thursday's close despite pulling back from a session high.

18 giu 2026, 22:06 UTC

Amgen Inc. shares are higher in after-market trading after notable volatility, contrasting with four consecutive lower closes. No specific news was identified for the move.

17 giu 2026, 19:53 UTC

Macro Event

Amgen Inc. shares are lower today, continuing a trend of declines amid the Federal Reserve's decision to hold interest rates steady.

16 giu 2026, 19:22 UTC

News

Amgen shares are lower following a jury ruling on patent infringement, despite positive Phase 3 data for Repatha and European approval for Imdylltra.

15 giu 2026, 21:09 UTC

Amgen Inc shares are trading higher in after-market hours. The broader market is gaining, driven by positive sentiment towards technology stocks and favorable geopolitical news.

12 giu 2026, 19:51 UTC

News

Amgen Inc. is reassessing data on Tavneos amid FDA scrutiny. Shares are higher as the company challenges the proposal to withdraw the drug's approval.

11 giu 2026, 23:06 UTC

News

Amgen engages Duke Clinical Research Institute to reassess Tavneos data amid FDA concerns, with shares trading higher in after-market hours.

10 giu 2026, 23:51 UTC

Amgen Inc. shares declined in after-market trading, continuing a trend of lower daily closes amid rising Treasury yields and weakness in technology stocks.

9 giu 2026, 19:56 UTC

News

Amgen Inc. shares are lower as Goldman Sachs cuts its price target to $389 from $425 amid an IRS audit disclosure affecting financial outlook.

8 giu 2026, 20:06 UTC

News

Amgen Inc. shares are lower today after presenting Phase 3 trial results showing Repatha's effectiveness in reducing cardiovascular event risk in high-risk diabetes patients.

5 giu 2026, 23:01 UTC

Amgen Inc shares are lower in after-market trading amid a broader equity sell-off following stronger-than-expected U.S. non-farm payroll data.

4 giu 2026, 23:51 UTC

News

Amgen will present at the Goldman Sachs Global Healthcare Conference on June 9, 2026. Shares are trading higher in after-market hours.

3 giu 2026, 23:41 UTC

Amgen Inc shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector and strong performance above its 20-day moving average.

2 giu 2026, 23:02 UTC

Amgen Inc. shares are lower in after-market trading, continuing a trend of declines over the last three sessions and remaining below the 20-day moving average.

1 giu 2026, 20:02 UTC

Amgen Inc. shares are lower today, dropping below Friday's close and nearing the lower end of their one-month trading range. No specific news was identified.

29 mag 2026, 20:06 UTC

Amgen Inc's shares are higher today, reflecting a slight gain since Thursday's close. The stock remains stable within its one-month trading range.

28 mag 2026, 23:56 UTC

Amgen Inc's shares are higher in after-market hours, maintaining stability above the 20-day moving average and within the one-month trading range.

27 mag 2026, 23:01 UTC

Amgen Inc shares are higher in after-market trading, influenced by broader market dynamics, including declining US Treasury yields and inflation concerns.

26 mag 2026, 19:56 UTC

News

Amgen Inc. shares are lower as rising bond yields reflect inflationary pressures. Analysts maintain a positive outlook on the company's drug pipeline and capital allocation.

22 mag 2026, 20:06 UTC

News

Amgen Inc. is trading higher amid scrutiny of its rare disease therapy, Tavneos, linked to patient deaths and regulatory restrictions on new prescriptions.

21 mag 2026, 19:13 UTC

News

Amgen Inc shares rose after Japan allowed new prescriptions for a rare-disease drug, reversing a previous recommendation linked to reported deaths.

20 mag 2026, 19:51 UTC

News

Amgen Inc. shares are higher following the appointment of Thomas Dittrich as CFO and strong revenue growth of 12.3% over the past two years.

19 mag 2026, 20:03 UTC

News
Social Media

Amgen Inc. shares are trading higher as analysts express optimism about revenue growth through 2027, despite a price target reduction to $427.

18 mag 2026, 19:52 UTC

Social Media
News

Amgen Inc shares are lower as safety concerns over Tavneos intensify. Kissei Pharmaceutical advised caution after reports of 20 deaths linked to the drug.

15 mag 2026, 23:26 UTC

Social Media

Amgen Inc shares are higher in after-market trading, despite social media concerns over recent decisions and a warning from Kissei Pharmaceutical regarding a rare drug.

14 mag 2026, 19:16 UTC

News

Amgen shares are lower as Piper Sandler cuts price target to $427 from $432. The stock is trading within its one-month range.

13 mag 2026, 23:02 UTC

Amgen Inc. shares are trading lower in after-market hours, following unusual activity earlier in the session and remaining below the 20-day moving average.

Confronto tra pari

Modifica del prezzo

Amgen Inc Previsione

Obiettivo di Prezzo

By TipRanks

1.69% in crescita

Previsioni per 12 mesi

Media 357.38 USD  1.69%

Alto 427 USD

Basso 300 USD

Basato su 24 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Amgen Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

24 ratings

10

Acquista

13

Mantieni

1

Vendi

Sentiment

By Acuity

104 / 342 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat